Nephro-Urology Monthly

Published by: Kowsar

Withania coagulans Extract Induces Cell Apoptosis and Inhibits COX-2 Expression in a Rat Model of Benign Prostatic Hyperplasia

Maryam Sarbishegi 1 , 2 , * , Ozra Khajavi 2 and Mohammad Reza Arab 1 , 2
Authors Information
1 Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, IR Iran
2 Department of Anatomy, School of Medicine, Zahedan University of Medical Sciences, Zahedan, IR Iran
Article information
  • Nephro-Urology Monthly: August 01, 2016, 8 (5); e39284
  • Published Online: August 24, 2016
  • Article Type: Research Article
  • Received: May 21, 2016
  • Accepted: June 25, 2016
  • DOI: 10.5812/numonthly.39284

To Cite: Sarbishegi M, Khajavi O, Arab M R. Withania coagulans Extract Induces Cell Apoptosis and Inhibits COX-2 Expression in a Rat Model of Benign Prostatic Hyperplasia, Nephro-Urol Mon. 2016 ; 8(5):e39284. doi: 10.5812/numonthly.39284.

Abstract
Copyright © 2016, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. De Nunzio C, Albisinni S, Gacci M, Tubaro A. The Role of Inflammation in the Progression of Benign Prostatic Hyperplasia. Current Bladder Dysfunction Reports. 2013; 8(2): 142-9[DOI]
  • 2. Briganti A, Capitanio U, Suardi N, Gallina A, Salonia A, Bianchi M, et al. Benign Prostatic Hyperplasia and Its Aetiologies. Eur Urol Supplements. 2009; 8(13): 865-71[DOI]
  • 3. Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009; 69(16): 1774-80[DOI][PubMed]
  • 4. McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 2007; 29(3): 387-98[PubMed]
  • 5. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol. 2006; 16(1): 25-9[PubMed]
  • 6. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004; 61(1): 60-72[DOI][PubMed]
  • 7. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995; 83(3): 493-501[PubMed]
  • 8. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 2003; 191(2): 125-35[PubMed]
  • 9. Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013; 111(2): 304-11[DOI][PubMed]
  • 10. Altavilla D, Minutoli L, Polito F, Irrera N, Arena S, Magno C, et al. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. Br J Pharmacol. 2012; 167(1): 95-108[DOI][PubMed]
  • 11. Allkanjari O, Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci. 2015; 126: 42-56[DOI][PubMed]
  • 12. van Breemen RB, Sharifi R, Viana M, Pajkovic N, Zhu D, Yuan L, et al. Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer Prev Res (Phila). 2011; 4(5): 711-8[DOI][PubMed]
  • 13. Beigomi M, Mohammadifar MA, Hashemi M, Senthil K, Valizadeh M. Biochemical and rheological characterization of a protease from fruits of Withania coagulans with a milk-clotting activity. Food Sci Biotechnol. 2014; 23(6): 1805-13
  • 14. Sarbishegi M, Khani M, Salimi S, Valizadeh M, Sargolzaei Aval F. Antiproliferative and Antioxidant Effects of Withania coagulans Extract on Benign Prostatic Hyperplasia in Rats. Nephrourol Mon. 2016; 8(1): 33180[DOI][PubMed]
  • 15. Sarbishegi M, Heidari Z, Mahmoudzadeh-Sagheb H, Valizadeh M, Doostkami M. Neuroprotective effects of Withania coagulans root extract on CA1 hippocampus following cerebral ischemia in rats. Avicenna J Phytomed. 2016; 6(4): 399-409[PubMed]
  • 16. Khodaei M, Jafari M, Noori M. Remedial use of withanolides from Withania coagolans (Stocks) Dunal. Adv Life Sci. 2012; 2(1): 6-19
  • 17. Roy RV, Suman S, Das TP, Luevano JE, Damodaran C. Withaferin A, a steroidal lactone from Withania somnifera, induces mitotic catastrophe and growth arrest in prostate cancer cells. J Nat Prod. 2013; 76(10): 1909-15[DOI][PubMed]
  • 18. Jayaprakasam B, Nair MG. Cyclooxygenase-2 enzyme inhibitory withanolides from Withania somnifera leaves. Tetrahedron. 2003; 59(6): 841-9
  • 19. Hardik S, Hardik M, Deepti J, Ghanashyam P. Pharmacological investigation of an Ayurvedic formulation on testosterone propionate-induced benign prostatic hyperplasia rats. J Exp Integr Med. 2014; 4(2): 131-6
  • 20. Funahashi Y, O'Malley KJ, Kawamorita N, Tyagi P, DeFranco DB, Takahashi R, et al. Upregulation of androgen-responsive genes and transforming growth factor-beta1 cascade genes in a rat model of non-bacterial prostatic inflammation. Prostate. 2014; 74(4): 337-45[DOI][PubMed]
  • 21. Veeresh Babu SV, Veeresh B, Patil AA, Warke YB. Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol. 2010; 626(2-3): 262-5[DOI][PubMed]
  • 22. Bahey NG, Soliman GM, El-Deeb TA, El-Drieny EA. Influence of insulin and testosterone on diabetic rat ventral prostate: Histological, morphometric and immunohistochemical study. J Micros Ultra. 2014; 2(3): 151-60[DOI]
  • 23. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev. 2003; 12(9): 933-9[PubMed]
  • 24. Zheng H, Xu W, Lin J, Peng J, Hong Z. Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis. Mol Med Rep. 2013; 7(3): 848-54[DOI][PubMed]
  • 25. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci. 2003; 74(1): 125-32[PubMed]
  • 26. Shukla K, Dikshit P, Shukla R, Sharma S, Gambhir JK. Hypolipidemic and antioxidant activity of aqueous extract of fruit of Withania coagulans (Stocks) Dunal in cholesterol-fed hyperlipidemic rabbit model. Indian J Exp Biol. 2014; 52(9): 870-5[PubMed]
  • 27. Jarvis TR, Chughtai B, Kaplan SA. Testosterone and benign prostatic hyperplasia. Asian J Androl. 2015; 17(2): 212-6[DOI][PubMed]
  • 28. Morales A. Androgen replacement therapy and prostate safety. Eur Urol. 2002; 41(2): 113-20[PubMed]
  • 29. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol. 2001; 39(4): 390-9[PubMed]
  • 30. Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003; 61(4 Suppl 1): 2-7[PubMed]
  • 31. Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol. 2007; 51(1): 207-15[DOI][PubMed]
  • 32. Al-Ansari AA, Shokeir AA. Noninvasive treatment of benign prostatic hyperplasia. Where do we stand in 2005. Saudi Med J. 2006; 27(3): 299-304[PubMed]
  • 33. Robert G, Salagierski M, Schalken JA, de La Taille A. Inflammation and benign prostatic hyperplasia: cause or consequence? [in French]. Prog Urol. 2010; 20(6): 402-7[DOI][PubMed]
  • 34. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004; 146(1-2): 1-12[PubMed]
  • 35. Taverna G, Giusti G, Seveso M, Hurle R, Colombo P, Stifter S, et al. Mast cells as a potential prognostic marker in prostate cancer. Dis Markers. 2013; 35(6): 711-20[DOI][PubMed]
  • 36. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008; 112(4): 1269-79[DOI][PubMed]
  • 37. Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res. 2011; 71(18): 5987-97[DOI][PubMed]
  • 38. Papadoukakis S, Kyroudi-Voulgari A, Truss MC, Perea D, Mitropoulos D. Quantitative study of mast cells in experimentally induced benign prostatic hyperplasia. Urol Int. 2010; 84(1): 100-4[DOI][PubMed]
  • 39. Ahmad MK, Mahdi AA, Shukla KK, Islam N, Rajender S, Madhukar D, et al. Withania somnifera improves semen quality by regulating reproductive hormone levels and oxidative stress in seminal plasma of infertile males. Fertil Steril. 2010; 94(3): 989-96[DOI][PubMed]
  • 40. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res. 2005; 11(9): 3250-6[DOI][PubMed]
  • 41. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 2000; 56(4): 671-6[PubMed]
  • 42. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate. 2002; 53(3): 232-40[DOI][PubMed]
  • 43. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998; 58(19): 4245-9[PubMed]
  • 44. Min KJ, Choi K, Kwon TK. Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells. Int Immunopharmacol. 2011; 11(8): 1137-42[DOI][PubMed]
  • 45. Oh JH, Kwon TK. Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappaB in human pulmonary epithelial cells. Int Immunopharmacol. 2009; 9(5): 614-9[DOI][PubMed]
  • 46. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res. 2001; 61(6): 2720-6[PubMed]
  • 47. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther. 2006; 5(6): 1434-45[DOI][PubMed]
  • 48. Mulabagal V, Subbaraju GV, Rao CV, Sivaramakrishna C, Dewitt DL, Holmes D, et al. Withanolide sulfoxide from Aswagandha roots inhibits nuclear transcription factor-kappa-B, cyclooxygenase and tumor cell proliferation. Phytother Res. 2009; 23(7): 987-92[DOI][PubMed]
  • 49. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol. 1996; 27(7): 668-75[PubMed]
  • 50. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35(4): 495-516[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments